Biotech Conference Coverage Day 4 Session 2 - Geron Corporation

GERN (update): Geron is primarily an independent growth story: Rytelo generated $57.5 million of Q2 net revenue, and guidance now points toward roughly $230-$240 million for the year as adoption expands into community practices that treat about 80% of relevant patients. A positive myelofibrosis interim analysis by year-end would be transformational, but continuation to final analysis in H2 2028 is management’s base case, leaving investors at risk of paying now for an option whose resolution may remain years away.

Read full article (2 min)